Next generation sequencing and the molecular tumor board from the point of view of oncologists

Česká verzia

Authors: Udmila Křížová; Luboš Petruželka
Authors place of work: Onkologická klinika VFN a 1. LF UK, Praha
Published in the journal: Čes.-slov. Patol., 57, 2021, No. 3, p. 144-146
Category: Reviews Article

Summary

Molecular genetic methods have evolved dramatically in the last decade. In particular, sequencing of the new generation - NGS has become a financially and technically available examination. Thus, it begins to be used in the clinical practice of many specializations, including oncology. The proper use of these methods is a way to personalized oncology – treatment of the patient based on the occurrence of specific genetic aberrations, which are confirmed in his cancer, regardless of the histopathological type of tumor. This principle is completely new in oncology and raises number of questions and problems. The interpretation of the results of molecular genetic examinations is very complex and demanding, and therefore new multidisciplinary teams, so-called molecular tumor boards, are being created. The worldwide standardization of these boards is currently underway. Recommendations regarding the indication of NGS examinations in oncology patients are also being set.At the European level in the form of ESMO recommendations and at the national level also. Personalized oncology is the future of this field, which will lead to the best treatment response and minimize side effects.

Keywords:

NGS – next generation sequencing – molecular tumor board – lung cancer – precision oncology – personalized therapy

Zdroje

1. Hodson R. Precision oncology. Nature 2020; 585(7826): S1-S1.

2. Stricker T, Catenacci D, Seiwert T. Molecular Profiling of Cancer – The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. Seminars in Oncology 2011; 38(2): 173-185.

3. Hanahan D, Weinberg R. Hallmarks of Cancer: The Next Generation. Cell 2011; 144(5): 646-674.

4. Koopman B, Groen H, Ligtenberg M, et al. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations. The Oncologist 2020, In Print.

5. van der Velden DL, van Herpen CML, van Laarhoven HWM, et al. Molecular Tumor Boards: current practice and future needs. Annals of Oncology 2017; 28(12): 3070-3075.

6. Kato S, Kim K, Lim HJ, et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of- One strategy. Nature Communications 2020; 11(1): 4965.

7. Vanderwalde A, Grothey A, Vaena D, Vidal G, Elnaggar A, Bufalino G, Schwartzberg L. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. Journal of Personalized Medicine 2020; 10(4): 252.

8. Knepper TC, Bell GC, Hicks JK, et al. Key Lessons Learned from Moffitt’s Molecular Tumor Board: The Clinical Genomics Action Committee Experience. The Oncologist 2017; 22(2): 144-151.

9. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology 2020; 31(11): 1491-1505.

10. Harada S, Arend R, Dai Q, et al. Implementation and utilization of the molecular tumor board to guide precision medicine. Oncotarget 2017; 8(34): 57845-57854.

11. Clynick B, Dessauvagie B, Sterrett G, Harvey NT, Allcock RJN, Saunders C, Erber W, Meehan K. Genetic characterisation of molecular targets in carcinoma of unknown primary. Journal of Translational Medicine 2018; 16(1): 185.

12. Casolino R, Braconi C, Malleo G, et al. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology 2021; 32(2): 183-196.

13. Dundr P, Matěj R, Němejcová K, Bártů M, Stružinská I. Predictive testing in non-small cell lung carcinoma. Klinická onkologie 2021; 34(Suppl 1): S29-S34.

14. Petruželka L, Špaček J, Křížová Ľ. Future of lung cancer treatment. Klinická onkologie [online] 2021; 34(Suppl 1): S71-81.

15. Dalton W B, M. Forde P, Kang H, et al. Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precision Oncology 2017; 2017: PO.16.00046.

16. Basse C, Morel C, Alt M, et al. Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie. ESMO Open 2018; 3(3): e000339.

17. Rieke D, Lamping M, Schuh M, et al. Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide. JCO Precision Oncology 2018; 2: 1-14.